Mylan settles with makers of cancer drug

Settlement with Pfizer, OSI, Genentech will result in suit's dismissal

PITTSBURGH — Mylan has settled with the makers of a drug used to treat cancer in a patent-infringement lawsuit, the generic drug maker said Wednesday.

Mylan said it had entered an agreement with Pfizer, Genentech and OSI that would allow their suit against Mylan over the drug Tarceva (erlotinib) to be dismissed. All other terms and conditions of the settlement are confidential, and the agreement is subject to Department of Justice and Federal Trade Commission review, Mylan said.

Tarceva is used along with the chemotherapy drug gemcitabine as a first-line treatment for locally advanced pancreatic cancer that has spread to other parts of the body but can't be removed through surgery.

The drug — in the 25-mg, 100-mg and 150-mg strengths — had sales of about $638.7 million during the 12-month period that ended in March, according to IMS Health.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

Login or Register to post a comment.